Loading...
Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $56.0K Total Trade · DGFT Verified
Sartaj Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $56.0K across 2 products in 1 therapeutic categories. Based on 18 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Carfilzomib ($32.9K), Lenvatinib ($23.1K), .
Sartaj Pharma Private Limited, established on February 7, 2022, is a private limited company headquartered in Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51909DL2022PTC393423. Its authorized and paid-up capital stands at ₹100,000 each, reflecting a modest financial foundation. The company's registered office is located at 1702-1703/215, S/F, Bhagirath Palace, Chandni Chowk, Delhi, 110006.
Sartaj Pharma specializes in the wholesale and manufacturing of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has developed a strong reputation for providing exceptional products and services, catering to a diverse clientele ranging from small businesses to multinational corporations. Their commitment to excellence has enabled them to distribute products to wholesalers and dealers globally, earning the trust of partners across various industries.
Sartaj Pharma Private Limited operates across 1 therapeutic categories, with Advanced Oncology (100.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Advanced Oncology
2 products · 100.0% · $56.0K
Sartaj Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Carfilzomib | Advanced Oncology | $32.9K | 7 | 2.7% | 2 |
| 2 | Lenvatinib |
Headquarters, ownership, manufacturing facilities, and key leadership
Sartaj Pharma Private Limited, established on February 7, 2022, is a private limited company headquartered in Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51909DL2022PTC393423. Its authorized and paid-up capital stands at ₹100,000 each, reflecting a modest financial foundation. The company's registered office is located at 1702-1703/215, S/F, Bhagirath Palace, Chandni Chowk, Delhi, 110006.
Sartaj Pharma specializes in the wholesale and manufacturing of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has developed a strong reputation for providing exceptional products and services, catering to a diverse clientele ranging from small businesses to multinational corporations. Their commitment to excellence has enabled them to distribute products to wholesalers and dealers globally, earning the trust of partners across various industries.
Sartaj Pharma Private Limited operates manufacturing facilities that produce a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding the locations and capacities of these facilities are not publicly disclosed, the company emphasizes its commitment to quality and innovation, ensuring that all products meet stringent international standards.
| $23.1K |
| 11 |
1.1% |
| 12 |
Sartaj Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $56.0K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Sartaj Pharma Private Limited.
Request DemoThe leadership team at Sartaj Pharma Private Limited comprises three directors:
These individuals bring a wealth of experience and strategic vision to the company, driving its growth and operational success. Their leadership is instrumental in steering Sartaj Pharma towards its mission of advancing healthcare through innovation and high-quality pharmaceutical products.
Regulated market presence, emerging market penetration, and geographic strategy
Sartaj Pharma Private Limited's export activities, as per TransData Nexus proprietary trade data, are primarily focused on the Advanced Oncology therapeutic category, with products like Carfilzomib and Lenvatinib. The company has engaged in 18 shipments totaling $56,000 USD, with Carfilzomib accounting for $33,000 USD and Lenvatinib for $23,000 USD. These figures indicate a concentrated portfolio, with the top two products representing 100% of the export value. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The company's focus on oncology products suggests potential interest in these regulated markets, but further information is needed to assess their market presence and regulatory standing in these regions.
Sartaj Pharma Private Limited's export data indicates a focus on the Advanced Oncology therapeutic category, with products like Carfilzomib and Lenvatinib. While specific details regarding the company's presence in emerging markets such as Africa, Latin America, and Southeast Asia are not publicly available, the company's emphasis on oncology products suggests potential interest in these regions. The World Health Organization's prequalification program could facilitate access to these markets, but further information is needed to assess Sartaj Pharma's engagement and regulatory standing in these areas.
Sartaj Pharma Private Limited's export data reveals a concentrated portfolio, with the top two products—Carfilzomib and Lenvatinib—accounting for 100% of the export value. This indicates a high level of concentration risk, as the company's revenue is heavily dependent on a limited number of products. The company's strategic direction appears to be focused on the oncology segment, particularly in the Advanced Oncology category. Diversifying the product portfolio and exploring additional therapeutic areas could mitigate concentration risks and enhance market resilience.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific details regarding Sartaj Pharma Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data indicates a focus on oncology products, which may require FDA approvals for the US market. However, without publicly accessible records, it is challenging to assess the company's regulatory standing with the FDA.
Sartaj Pharma Private Limited's commitment to quality is evident through its ISO 9001:2015 certification. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. These certifications are crucial for accessing international markets and ensuring product quality. The absence of publicly accessible records makes it difficult to assess the company's compliance with these international standards.
Sartaj Pharma Private Limited is registered with the Ministry of Corporate Affairs (MCA) under the Corporate Identification Number (CIN) U51909DL2022PTC393423. The company's authorized and paid-up capital is ₹100,000 each, reflecting a modest financial foundation. Specific details regarding manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. These regulatory approvals are essential for the company's operations and export activities. The lack of publicly accessible records makes it challenging to assess the company's compliance with Indian regulatory requirements.
As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Sartaj Pharma Private Limited. The absence of such records suggests that the company has maintained compliance with regulatory standards. However, without access to detailed inspection histories and regulatory filings, it is difficult to provide a comprehensive assessment of the company's regulatory standing.
Market share comparison, key differentiators, and strategic analysis
Sartaj Pharma Private Limited operates in the competitive pharmaceutical industry, focusing on oncology products such as Carfilzomib and Lenvatinib. While specific market share data and a detailed competitive analysis are not publicly available, the company's concentrated product portfolio indicates a niche focus within the oncology segment. To enhance its competitive position, Sartaj Pharma could consider diversifying its product offerings and expanding into additional therapeutic areas.
Sartaj Pharma Private Limited's key differentiators include its specialization in oncology products, particularly in the Advanced Oncology category, and its commitment to quality, as evidenced by its ISO 9001:2015 certification. The company's focus on high-quality pharmaceutical formulations and its ability to cater to a diverse clientele are also notable strengths. However, the lack of publicly available information regarding regulatory approvals and certifications makes it challenging to fully assess the company's competitive advantages.
Sartaj Pharma Private Limited's current strategic direction appears to be focused on the generics segment, with a particular emphasis on oncology products. The company's concentrated product portfolio suggests a niche market approach. To strengthen its strategic position, Sartaj Pharma could consider diversifying its product offerings, exploring additional therapeutic areas, and obtaining necessary regulatory approvals to access broader markets. This approach could enhance the company's growth prospects and market resilience.
Track record assessment, certifications to verify, and pre-order checks
Sartaj Pharma Private Limited has demonstrated a track record in exporting pharmaceutical formulations, with 18 shipments totaling $56,000 USD. The company's focus on oncology products indicates a specialized approach to product development and export. However, the lack of publicly available information regarding manufacturing facilities, regulatory approvals, and certifications makes it challenging to fully assess the company's reliability and consistency as a supplier. Prospective partners should conduct thorough due diligence to ensure alignment with quality standards and regulatory requirements.
Importers should verify the following certifications to ensure product quality and regulatory compliance:
Sartaj Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Carfilzomib ($32.9K), Lenvatinib ($23.1K). Total export value is $56.0K.
Sartaj Pharma Private Limited's total pharmaceutical export value is $56.0K, based on 18 verified shipments recorded in Indian Customs (DGFT) data.
Sartaj Pharma Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
1 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.